Statement of Changes in Beneficial Ownership (4)
March 03 2021 - 4:46PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Pepia John C |
2. Issuer Name and Ticker or Trading Symbol
MEDNAX, INC.
[
MD
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Principal Accounting Officer |
(Last)
(First)
(Middle)
1301 CONCORD TERRACE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/1/2021 |
(Street)
SUNRISE, FL 33323
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 3/1/2021 | | A(1) | | 10204 | A | $0.00 | 120653 | D | |
Common Stock | 3/1/2021 | | A(2) | | 10205 | A | $0.00 | 130858 | D | |
Common Stock | 3/1/2021 | | F(3) | | 2568 | D | $24.43 | 128573 (4) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 5,102 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2022, twenty-five percent (25%) on March 1, 2023 and fifty percent (50%) on March 1, 2024, subject to the terms of the Plan. |
(2) | Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024. |
(3) | Represents 2,568 shares withheld for payment of taxes upon vesting of shares previously reported. |
(4) | Includes 283 shares acquired by Reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Pepia John C 1301 CONCORD TERRACE SUNRISE, FL 33323 |
|
| Principal Accounting Officer |
|
Signatures
|
/s/ Dominic J. Andreano, Attorney-in-Fact | | 3/3/2021 |
**Signature of Reporting Person | Date |
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jul 2023 to Jul 2024